- $295.75m
- $319.58m
- $0.11m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2,525.63 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -123.38% | ||
Return on Equity | -3383.08% | ||
Operating Margin | -141098.16% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.11 | 0.06 | 0.07 | 0.09 | 0.11 | 0.18 | 16.38 | -34.31% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Directors
- Jeremy Levin NEC (68)
- Megan Baldwin CEO
- Karen Adams VFN
- Richard Chadwick OTH
- Mike Gerometta OTH
- Annette Leahy OTH
- Ian Leitch OTH
- Clare Price OTH
- Judith Robertson OTH (61)
- Lawrence Gozlan NID
- Julia Haller NID (66)
- Michael Sistenich NID
- Daniel Spiegelman NID (62)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 17th, 1984
- Public Since
- April 9th, 1985
- No. of Shareholders
- 7,448
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 662,808,634
- Address
- Suite 0403, MELBOURNE, 3141
- Web
- https://opthea.com/
- Phone
- +61 398260399
- Auditors
- Deloitte Touche Tohmatsu
Similar to OPT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:16 UTC, shares in Opthea are trading at $3.78. This share price information is delayed by 15 minutes.
Shares in Opthea last closed at $3.78 and the price had moved by -10% over the past 365 days. In terms of relative price strength the Opthea share price has underperformed the S&P500 Index by -31.72% over the past year.
The overall consensus recommendation for Opthea is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Opthea does not currently pay a dividend.
Opthea does not currently pay a dividend.
Opthea does not currently pay a dividend.
To buy shares in Opthea you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.78, shares in Opthea had a market capitalisation of $295.75m.
Here are the trading details for Opthea:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OPT
Based on an overall assessment of its quality, value and momentum Opthea is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Opthea is $12.70. That is 235.87% above the last closing price of $3.78.
Analysts covering Opthea currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opthea. Over the past six months, its share price has outperformed the S&P500 Index by +84.26%.
As of the last closing price of $3.78, shares in Opthea were trading +42.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Opthea PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Opthea's management team is headed by:
- Jeremy Levin - NEC
- Megan Baldwin - CEO
- Karen Adams - VFN
- Richard Chadwick - OTH
- Mike Gerometta - OTH
- Annette Leahy - OTH
- Ian Leitch - OTH
- Clare Price - OTH
- Judith Robertson - OTH
- Lawrence Gozlan - NID
- Julia Haller - NID
- Michael Sistenich - NID
- Daniel Spiegelman - NID